Compare Amgen, Inc. (AMGN) vs Hasbro, Inc. (HAS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Hasbro, Inc. — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Hasbro, Inc. trades at $78.76 (market cap $11.17B). The key difference: Amgen, Inc. is far larger — about 17.6× Hasbro, Inc.'s market cap, and Hasbro, Inc. pays the higher dividend (3.55%). Which is the better fit depends on your goals.
| AMGN | HAS | |
|---|---|---|
Market Cap | $196.12B | $11.17B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $105.88 |
52-Week Low | $271.18 | $70.95 |
Enterprise Value | $241.41B | $13.44B |
Dividend Yield | 2.77% | 3.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Hasbro (HAS) trades at $78.96, up 2.03% today, with a bearish technical signal but bullish oscillators suggesting potential reversal. The company reported negative net income of -$322.4M in 2025 despite revenue growth to $4.7B. Recent earnings beats and a $0.70 dividend highlight operational resilience, while analyst consensus targets $104.80. News highlights include new product launches like Blooms by Play-Doh and strong performance in the Wizards segment.
Outlook: Upside exists from analyst targets and earnings momentum, but risks include high debt, margin pressure, and competitive threats. The stock presents a contrarian opportunity if operational improvements continue, though volatility near key support at $76 warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →
